University of Oulu

Rajamäki, A, Kuitunen, H, Sorigue, M, Kokkonen, S-M, Kuittinen, O, Sunela, K. FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma. Cancer Med. 2023; 12: 407-411. doi: 10.1002/cam4.4924

FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

Saved in:
Author: Rajamäki, Aino1,2; Kuitunen, Hanne3; Sorigue, Marc4;
Organizations: 1Department of Oncology, Hospital Nova of Central Finland, Jyväskylä, Finland
2Institute of Clinical Medicine, Faculty of Health Medicine, University of Eastern Finland, Kuopio, Finland
3Department of Oncology, Oulu University Hospital, Oulu, Finland
4Department of Hematology, ICO-Hospital Germans Trias i Pujol, Functional cytomics-IJC, Badalona, Spain
5Department of Nuclear Medicine, Oulu University Hospital, Oulu, Finland
6Medical Research Centre and Cancer and Translational Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland
7Department of Oncology, Kuopio University Hospital, Kuopio, Finland
8Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.4 MB)
Persistent link:
Language: English
Published: John Wiley & Sons, 2022
Publish Date: 2023-08-17


Aim: The purpose of the study was to evaluate the clinical impact of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) followed by a new biopsy from the site with maximum standardized uptake value (SUVmax) in case of high maximal SUV values, in detecting clinically unsuspected histologic transformations (HT) of follicular lymphoma (FL).

Methods: This retrospective study included all the patients who had undergone FDG-PET/CT during primary diagnosis or relapse of FL between 2010 and 2020 at Oulu University Hospital.

Results: The diagnosis changed from an indolent disease to a transformed lymphoma in >10% (7/63) of the patients who underwent diagnostic FDG-PET/CT. The HT risk associated with high SUVmax (>10) was 24% (7 of 29 performed biopsies). Four out of these seven patients with verified HT had no previous clinical suspicion of transformation.

Conclusion: Our results suggest that a rebiopsy based on a high SUVmax in diagnostic FDG-PET/CT is valuable in detecting clinically unsuspected HT of FL.

see all

Series: Cancer medicine
ISSN: 2045-7634
ISSN-E: 2045-7634
ISSN-L: 2045-7634
Volume: 12
Issue: 1
Pages: 407 - 411
DOI: 10.1002/cam4.4924
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Funding: This work was funded by the Finnish Blood Disease Research Foundation and Northern-Savonia Cancer Society (A.R.). Other authors disclose no special funding for this research.
Copyright information: © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.